The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

Pfizer, 23andMe start building 5,000-person lupus database

Pfizer and 23andMe have begun enrolling people in their lupus study. The partners aim to recruit 5,000 people into the study of the genetics of lupus over the next 12 months, in part by asking existing 23andMe customers to participate.

Pfizer settles lawsuits tying sex and gambling addictions to dopamine meds

Pfizer is settling class-action litigation brought by patients who claimed the drugmaker did not adequately warn them of possible side effects of drugs they were taking to treat their Parkinson's disease or restless leg syndrome.

Big Pharma's cardiovascular sales ain't what they used to be

Slumping sales for cardiovascular drugs isn't exactly a new phenomenon for Big Pharma, with some of the industry's top drugmakers suffering from recent patent expirations. But a new report shows which CV franchises have been hurt the most. 

Pfizer taps new R&D leaders as Gutiérrez-Ramos heads back into biotech

José-Carlos Gutiérrez-Ramos, Pfizer's prominent head of BioTherapeutics R&D in Cambridge, MA, is leaving the pharma giant and jumping into the booming biotech world, prompting a promotion inside the multibillion-dollar research group.

23andMe, Pfizer recruiting patients for joint genetic study of lupus patients

Controversial genetic testing company 23andMe is finding new ways to stay relevant after the FDA yanked its popular--and once lucrative--direct-to-consumer diagnostic from the market in 2013.

The Q1 drug launch scorecard, starring Sanofi, Lilly, Pfizer, Gilead, Merck and more

It's the big numbers that tend to make headlines during earnings season: Overall sales, top-selling meds, and, of course, earnings per share. Some closely watched new drugs have a moment in the sun, too. But other launches? Barely a glimpse--if any at all. Here's a roundup of the launch stats that caught our eyes.

Pfizer's Viagra keeps generics at bay in China, with sales up 47%

Pfizer's Viagra sales may be suffering from generic rivals in Europe. But the brand is still going gangbusters in China, helping to soften the blow.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1 (Part 4)

FiercePharmaAsia  combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.

UPDATED: Big deal, small deal, any kind of good deal would help ready Pfizer for the Big Split

No one can pin down Pfizer CEO Ian Read when it comes to whether the company will split up--not publicly, anyway. That word won't come till late next year at least. But repeated questioning from analysts during the company's first-quarter earnings call did yield some facts in the matter.

Hospira's Rocky Mount warning letter lifted; Pfizer benefits

Hospira has worked itself out from under the warning letters for its pharma manufacturing plants in Rocky Mount and Clayton, NC. That means that Pfizer, which is buying Hospira in a $17 billion deal, will not have that hanging over its head, although the company still has plenty of other regulatory issues with which Pfizer will have to contend.